Coverage with Evidence Development (CED) is a policy approach used by the Centers for Medicare & Medicaid Services (CMS) to provide conditional coverage of certain medical technologies and services. This approach allows Medicare beneficiaries access to promising but not yet fully proven treatments while additional evidence is gathered to determine their effectiveness and value.

CED is particularly relevant in the context of new medical technologies, diagnostic tests, and procedures that may show potential benefits but lack comprehensive evidence to support broad coverage. By implementing CED, CMS aims to balance the need for innovation in healthcare with the necessity of ensuring that Medicare funds are used effectively and efficiently.

Under the CED framework, CMS provides provisional coverage for a treatment or technology while requiring the collection of additional data. This data collection is typically done through clinical studies or registries, which help to ascertain the real-world effectiveness and safety of the intervention. The evidence gathered can then inform future coverage decisions, potentially leading to permanent and broader Medicare coverage if the results are favorable.

The CED process begins with a National Coverage Determination (NCD), which is a formal decision by CMS regarding whether a particular item or service is covered nationally under Medicare. If an NCD determines that evidence is insufficient to support full coverage, CMS may opt for CED, allowing conditional coverage while evidence is collected. This approach ensures that beneficiaries have access to potentially beneficial treatments without waiting for the often lengthy process of gathering conclusive evidence.

One of the key benefits of CED is that it encourages innovation in the healthcare industry. By providing a pathway for new technologies to be covered under Medicare, CED supports the development and adoption of cutting-edge treatments. This can lead to improved patient outcomes and the advancement of medical knowledge.

However, CED also presents challenges. The requirement for additional data collection can be burdensome for healthcare providers and researchers. It may involve complex study designs, patient recruitment, and long follow-up periods, which can increase costs and delay the availability of new treatments. Moreover, the uncertainty surrounding coverage can be a barrier for manufacturers and investors, potentially hindering the development of new technologies.

Despite these challenges, CED remains a crucial tool for CMS in managing the introduction of new medical technologies. It allows for a measured approach to coverage, ensuring that Medicare beneficiaries have access to promising treatments while maintaining the integrity of the Medicare program.

In conclusion, Coverage with Evidence Development is a strategic policy that balances the need for innovation with the imperative of evidence-based decision-making. By allowing conditional coverage of new treatments while additional data is collected, CMS ensures that Medicare beneficiaries can access cutting-edge healthcare solutions without compromising the program's sustainability.

Sources

• Coverage with evidence development - CMS provides an overview of how CED works and its role in Medicare coverage decisions.